These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
136 related items for PubMed ID: 975068
41. Low concentrations of actinomycin D potentially cause therapeutic differentiation in human rhabdomyosarcoma cell line RD. Melguizo C, Prados J, Marchal JA, Aránega AE, Alvarez L, Aránega A. Pathol Res Pract; 1996 Feb; 192(2):188-94. PubMed ID: 8692721 [Abstract] [Full Text] [Related]
42. Drug-containing lipid vesicles render drug-resistant cell sensitive to actinomycin D. Poste G, Papahadjopoulos D. Nature; 1976 Jun 24; 261(5562):699-701. PubMed ID: 934317 [No Abstract] [Full Text] [Related]
43. Membrane-mediated drug resistance and phenotypic reversion to normal growth behavior of Chinese hamster cells. Biedler JL, Riehm H, Peterson RH, Spengler BA. J Natl Cancer Inst; 1975 Sep 24; 55(3):671-80. PubMed ID: 1159844 [Abstract] [Full Text] [Related]
44. A model for the kinetics of distribution of actinomycin-D in the beagle dog. Lutz RJ, Galbraith WM, Dedrick RL, Shrager R, Mellett LB. J Pharmacol Exp Ther; 1977 Mar 24; 200(3):469-78. PubMed ID: 557542 [Abstract] [Full Text] [Related]
45. Studies on the mechanism of actinomycin D resistance of an SV40-transformed hamster cell line. Cremisi C, Sonenshein GE, Tournier P. Exp Cell Res; 1974 Nov 24; 89(1):89-94. PubMed ID: 4373262 [No Abstract] [Full Text] [Related]
46. [Synergistic effect of amphotericin B and actinomycin-D against two human choriocarcinoma cell lines]. Matsui H, Shirotake S, Kobayashi O, Sekiya S, Takamizawa H. Nihon Sanka Fujinka Gakkai Zasshi; 1987 Jan 24; 39(1):36-42. PubMed ID: 3819512 [Abstract] [Full Text] [Related]
47. Cell killing by actinomycin D in relation to the growth cycle of chinese hamster cells. Elkind MM, Kano E, Sutton-Gilbert H. J Cell Biol; 1969 Aug 24; 42(2):366-77. PubMed ID: 5792326 [Abstract] [Full Text] [Related]
48. Effect of actinomycin D and neoarsphenamine on tumor control and skin tolerance in the rat. Moulder JE, Lo PS, Fischer JJ. Cancer Treat Rep; 1978 May 24; 62(5):713-9. PubMed ID: 148967 [Abstract] [Full Text] [Related]
49. Increased uptake of actinomycin D in Ehrlich ascites tumour cells induced by daunorubicin. Lund-Andersen C, Skovsgaard T, Nissen NI. Cancer Chemother Pharmacol; 1983 May 24; 10(2):79-83. PubMed ID: 6831629 [Abstract] [Full Text] [Related]
50. On the differential cytotoxicity of actinomycin D. Sawicki SG, Godman GC. J Cell Biol; 1971 Sep 24; 50(3):746-61. PubMed ID: 4398631 [Abstract] [Full Text] [Related]
52. Inhibition of Pichinde virus replication by actinomycin D. Rawls WE, Banerjee SN, McMillan CA, Buchmeier MJ. J Gen Virol; 1976 Dec 24; 33(3):421-34. PubMed ID: 1003168 [Abstract] [Full Text] [Related]
53. Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells. Safa AR, Glover CJ, Meyers MB, Biedler JL, Felsted RL. J Biol Chem; 1986 May 15; 261(14):6137-40. PubMed ID: 3700389 [Abstract] [Full Text] [Related]
54. [Actinomycin D and 6-mercaptopurine-resistant Djungarian hamster cell line: karyotype, morphology, malignancy]. Kakpakova ES, Massino IuS, Malalhova EM. Genetika; 1981 May 15; 17(3):460-8. PubMed ID: 6941912 [Abstract] [Full Text] [Related]